Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.

[1]  D. A. Korevaar,et al.  Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes , 2015, European Respiratory Journal.

[2]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[3]  S. Fowler,et al.  High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. , 2015, The Journal of allergy and clinical immunology.

[4]  D. Khatry,et al.  High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. , 2014, The journal of allergy and clinical immunology. In practice.

[5]  W. Busse,et al.  Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. , 2014, The Lancet. Respiratory medicine.

[6]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[7]  E. Rawlins,et al.  The best laid schemes of airway repair , 2014, European Respiratory Journal.

[8]  C. Janson,et al.  Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. , 2013, The Journal of allergy and clinical immunology.

[9]  M. Humbert,et al.  Anti-interleukin-5 therapy in severe asthma , 2013, European Respiratory Review.

[10]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[11]  L. Boulet,et al.  Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.

[12]  Viswanath Devanarayan,et al.  Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. , 2011, Journal of pharmaceutical and biomedical analysis.

[13]  Lakshmi Amaravadi,et al.  Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. , 2011, Journal of immunological methods.

[14]  A. Rahman,et al.  A novel homogeneous Biotin-digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum. , 2010, Journal of immunological methods.

[15]  G. Walsh.  Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. , 2009, Current opinion in molecular therapeutics.

[16]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[17]  Viswanath Devanarayan,et al.  Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.

[18]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[19]  K. Takatsu,et al.  IL-5 and eosinophilia. , 2008, Current opinion in immunology.

[20]  S. Wenzel,et al.  Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. , 2004, The Journal of allergy and clinical immunology.

[21]  D. Postma,et al.  Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. , 2003, American journal of respiratory and critical care medicine.

[22]  R. Djukanović,et al.  The relationship between airways inflammation and asthma severity. , 2000, American journal of respiratory and critical care medicine.

[23]  R. Egan,et al.  Effect of Sch 55700, a Humanized Monoclonal Antibody to Human Interleukin-5, on Eosinophilic Responses and Bronchial Hyperreactivity , 1999, Arzneimittelforschung.

[24]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[25]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[26]  C. Ulrik.  Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[27]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.